BIOGEN IDEC INC. - HEMOPHILIA THERAPEUTIC AREA

Biogen Idec acquired Syntonix Pharmaceuticals in 2007, forming Biogen Idec's hemophilia therapeutic area around Syntonix' Fc fusion technology platform. While Fc fusion technology has been used for many years in approved products such as Enbrel™, Amevive® and Orencia®, Syntonix's proprietary monomeric Fc fusion technology has the potential to deliver enhanced pharmacodynamic properties when applied to recombinant coagulation factors. Operating as a wholly-owned subsidiary, Biogen Idec's hemophilia therapeutic area leverages the capabilities and global reach of Biogen Idec to translate the great promise of this technology into substantial improvements in treatment options and quality of life for the hemophilia community.

Our mission is to empower people with hemophilia to live the lives they choose. Our goal is to transform hemophilia management by using our proprietary Fc fusion technology to develop long-acting, fully-recombinant clotting factors.

Biogen Idec is committed to developing innovative treatments for patients with high unmet medical needs. For 30 years, we have been focused on transforming scientific discoveries into advances in human healthcare through the discovery, development and commercialization of our own pioneering products and through strategic alliances. Our hemophilia therapeutic area is focused on the discovery and development of innovative, long-acting therapies to treat hemophilia.

Biogen Idec Hemophilia is developing innovative, fully recombinant clotting factor replacement products that are being explored for their potential to provide prolonged protection from bleeding. These investigational products are Fc fusions of the Fc component of human IgG and a clotting factor.

clinical trial is a research study conducted to answer specific questions about new treatments, or to investigate new ways of using known treatments. In most cases, the therapies and drugs investigated in clinical trials are not approved by Regulatory Agencies (such as the Food and Drug Administration (FDA) in the United States), and the benefits and risks of taking the treatment are not yet confirmed. Clinical trials are used to determine whether new treatments are safe and effective. The knowledge gained from clinical trials regarding the safety and efficacy of new treatments or drugs ultimately may allow pharmaceutical companies to offer new and better options to patients.